The Medtronic Foundation and Children’s Heartlink Focus New Partnership on Health Equity for 10,000 Children and 10,000 Health Workers in Underserved Countries

April 7, 2021

The Medtronic Foundation: As the World Health Organization spearheads a global campaign on equity this World Health Day, the Medtronic Foundation and Children’s HeartLink (CHL) are announcing a $2.5 million, three-year, outcomes-based partnership to address congenital heart disease in children with a focus on reducing disparities in access to care and quality patient outcomes, and meaningful employee engagement.

This partnership continues a rich collaborative legacy across the organizations and is made in honor of Omar Ishrak, former chairman and CEO, Medtronic and former board member of the Medtronic Foundation, a true champion of impact-driven philanthropy focusing on the underserved. View video.

“Every child with congenital heart disease deserves access to quality pediatric heart care,” said Paurvi Bhatt, Medtronic Foundation president. “Together with Children’s HeartLink, the Medtronic Foundation is in a unique position to mark World Health Day by ensuring more children get equitable care and have the opportunity to survive and thrive.”

Worldwide, the leading cause of death from a non-communicable disease before age 30 is congenital heart disease.1 Ninety percent of children born with heart disease don’t have access to the care they need, and most of those children live in low- and middle-income countries.2

“We are especially proud because this partnership brings together both the financial resources from the Medtronic Foundation and the time and skills of our passionate Medtronic employees. Together, we can improve quality care and patient outcomes,” said Geoff Martha, Medtronic chairman and CEO, and member of, CHL board of directors.

“We are honored to partner with Medtronic Foundation and help thousands of more children, and the impact of health worker training will be felt for generations to come,” said Jackie Boucher, Children’s HeartLink president. “This partnership gives 10,000 children the chance for a joyful childhood and the opportunity to lead productive adult lives.”

Specifically, the partners aim to actively address inequities in congenital heart surgery access and outcomes over three years by:

  • Strengthening hospital capacity and training 10,000 health workers (pediatric surgeons, pediatric cardiologists, and nurses) to provide congenital heart disease surgery and quality outcomes for 10,000 children.
  • Supporting CHL’s strategic growth and innovation, enabling the organization to scale in underserved countries – doubling its impact between 2025 and 2030 by adding five new partner hospitals over the next 3 years.
  • Reducing health disparities in access to care through a mixed-method study with partner hospitals, revealing key differences by gender, income, and socioeconomic status of families, and developing site-specific equity dashboards to foster continuous quality improvement.
  • Tapping Medtronic employees’ skills and talents in domains such as clinical and medical education and training, technology development, market access, data science, and analytics.

Hot this week

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution